Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $FGEN
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2023 | $4.00 → $2.00 | Neutral → Underperform | BofA Securities |
6/26/2023 | Buy → Hold | Stifel | |
6/26/2023 | Buy → Neutral | BofA Securities | |
6/26/2023 | Outperform → Mkt Perform | Raymond James | |
6/26/2023 | Outperform → Mkt Perform | William Blair | |
6/2/2023 | $23.00 → $32.00 | Hold → Buy | Stifel |
1/31/2023 | Mkt Perform → Outperform | William Blair | |
1/26/2023 | $35.00 | Mkt Perform → Outperform | Raymond James |
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Company's cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024FibroGen to host conference call and webcast presentation today at
FibroGen downgraded by BofA Securities with a new price target
BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously
FibroGen downgraded by Stifel
Stifel downgraded FibroGen from Buy to Hold
FibroGen downgraded by BofA Securities
BofA Securities downgraded FibroGen from Buy to Neutral
CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
Chief Medical Officer Adib Deyaa bought $25,884 worth of shares (22,123 units at $1.17), increasing direct ownership by 37% to 82,123 units (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
CEO Wettig Thane bought $50,663 worth of shares (145,000 units at $0.35), increasing direct ownership by 36% to 543,329 units (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
Director Schoeneck James A bought $105,040 worth of shares (300,000 units at $0.35) (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
CEO Wettig Thane covered exercise/tax liability with 22,405 shares and was granted 781 shares, decreasing direct ownership by 5% to 398,329 units (SEC Form 4)
4 - FIBROGEN INC (0000921299) (Issuer)
SEC Form 10-K filed by FibroGen Inc
10-K - FIBROGEN INC (0000921299) (Filer)
FibroGen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
8-K - FIBROGEN INC (0000921299) (Filer)
SEC Form 8-K filed by FibroGen Inc
8-K - FIBROGEN INC (0000921299) (Filer)
FibroGen Appoints David DeLucia as Chief Financial Officer
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him
FibroGen Announces Leadership Transition
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period. "Than
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Company's cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024FibroGen to host conference call and webcast presentation today at
Amendment: SEC Form SC 13G/A filed by FibroGen Inc
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
Amendment: SEC Form SC 13G/A filed by FibroGen Inc
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
Amendment: SEC Form SC 13G/A filed by FibroGen Inc
SC 13G/A - FIBROGEN INC (0000921299) (Subject)